US 10,376,576 B2
Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis B virus infection
Wilhelmus Johannes Theodorus Alexander Krebber, Leiden (NL); Johan Herman Kessler, Leiden (NL); Cornelis Joseph Maria Melief, Haarlem (NL); and Kitty Michelle Corinne Kwappenberg, Leiden (NL)
Assigned to ISA Pharmaceuticals B.V., Leiden (NL)
Appl. No. 15/315,526
Filed by ISA Pharmaceuticals B.V., Leiden (NL)
PCT Filed Jun. 1, 2015, PCT No. PCT/NL2015/050390
§ 371(c)(1), (2) Date Dec. 1, 2016,
PCT Pub. No. WO2015/187009, PCT Pub. Date Dec. 10, 2015.
Claims priority of application No. 14170733 (EP), filed on Jun. 2, 2014.
Prior Publication US 2017/0246293 A1, Aug. 31, 2017
Int. Cl. A61K 39/29 (2006.01); C07K 11/00 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/292 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/572 (2013.01); C12N 2730/10134 (2013.01)] 25 Claims
 
1. An immunogenic pharmaceutical composition comprising:
(a) a peptide of at least 30 and at most 40 amino acids in length and comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 51-79, 1142-1145 and 1468-1471,
(b) an immune-stimulating amount of at least one pharmaceutically acceptable adjuvant selected from the group consisting of a human toll-like receptor ligand and/or agonist, Montanide ISA-51, Montanide ISA-720, dsRNA, cyclic dinucleotides (CDNs), Muramyl dipeptide (MDP), a tetanus toxin derived peptide, Interferon alpha (INFα), and combinations thereof.